Analysts' corner

IDFC & Biocon

IDFC
Reco price/date: Rs 116/May 21;
Current/Target price: Rs 120.4/Rs 147
IDFC has delivered strong performance on growth and margin front. Expected monetary easing and reformatory steps by the government would be major catalysts in further improving the growth and profitability outlook. Healthy asset quality track record and prudent provisioning policy makes IDFC better placed compared to its peers in infra financing. The growth in IDFC’s outstanding disbursements remained well-diversified across telecom, energy and transportation segments. Analysts expect IDFC to report an EPS of Rs 11 and Rs 13 and estimated adjusted book value (for investment in other ventures) of Rs 82 and Rs 92 for 2012-13 and 2013-14, respectively. Maintain Buy.

Motilal Oswal Securities

BIOCON
Reco price/date: Rs 217/May 21;
Current/Target price: Rs 215/Rs 186
Biocon's (BIOS) shares have had an uninspiring run after the termination of the Pfizer deal, which dealt a big blow to its biosimilar insulin aspirations. While the deal is now terminated, it would continue to throw its shadow over future earnings, thanks to an aggressive accounting policy that would see BIOS shift biosimilar insulin R&D costs off the P&L. This, along with use of a creative transaction structure for AxiCorp, leaves analyst frustrated with corporate governance standards in the company, and they have downgraded their accounting and corporate governance rating from amber to red. Stripping out biosimilar insulin (90 per cent valuation haircut) and Dificid, BIOS is currently trading at 12 times FY13 estimated earnings. Espirito has cut its fair value by 47 per cent to Rs 186 (from Rs 350 earlier). Downgrade to sell.

Espirito Santo Securities


Note: Reco price/date refers to the price and date at which the recommendation was made. Target price refers to the fair value of the stock as per the said brokerage

image
Business Standard
177 22
Business Standard

Analysts' corner

IDFC & Biocon

SI Team  |  Mumbai 



IDFC
Reco price/date: Rs 116/May 21;
Current/Target price: Rs 120.4/Rs 147


IDFC has delivered strong performance on growth and margin front. Expected monetary easing and reformatory steps by the government would be major catalysts in further improving the growth and profitability outlook. Healthy asset quality track record and prudent provisioning policy makes IDFC better placed compared to its peers in infra financing. The growth in IDFC’s outstanding disbursements remained well-diversified across telecom, energy and transportation segments. Analysts expect IDFC to report an EPS of Rs 11 and Rs 13 and estimated adjusted book value (for investment in other ventures) of Rs 82 and Rs 92 for 2012-13 and 2013-14, respectively. Maintain Buy.

Motilal Oswal Securities

BIOCON
Reco price/date: Rs 217/May 21;
Current/Target price: Rs 215/Rs 186
Biocon's (BIOS) shares have had an uninspiring run after the termination of the Pfizer deal, which dealt a big blow to its biosimilar insulin aspirations. While the deal is now terminated, it would continue to throw its shadow over future earnings, thanks to an aggressive accounting policy that would see BIOS shift biosimilar insulin R&D costs off the P&L. This, along with use of a creative transaction structure for AxiCorp, leaves analyst frustrated with corporate governance standards in the company, and they have downgraded their accounting and corporate governance rating from amber to red. Stripping out biosimilar insulin (90 per cent valuation haircut) and Dificid, BIOS is currently trading at 12 times FY13 estimated earnings. Espirito has cut its fair value by 47 per cent to Rs 186 (from Rs 350 earlier). Downgrade to sell.

Espirito Santo Securities


Note: Reco price/date refers to the price and date at which the recommendation was made. Target price refers to the fair value of the stock as per the said brokerage

RECOMMENDED FOR YOU

Analysts' corner

IDFC & Biocon

IDFC has delivered strong performance on growth and margin front. Expected monetary easing and reformatory steps by the government would be major catalysts in further improving the growth and profitability outlook. Healthy asset quality track record and prudent provisioning policy makes IDFC better placed compared to its peers in infra financing. The growth in IDFC’s outstanding disbursements remained well-diversified across telecom, energy and transportation segments. Analysts expect IDFC to report an EPS of Rs 11 and Rs 13 and estimated adjusted book value (for investment in other ventures) of Rs 82 and Rs 92 for 2012-13 and 2013-14, respectively. Maintain Buy.

IDFC
Reco price/date: Rs 116/May 21;
Current/Target price: Rs 120.4/Rs 147
IDFC has delivered strong performance on growth and margin front. Expected monetary easing and reformatory steps by the government would be major catalysts in further improving the growth and profitability outlook. Healthy asset quality track record and prudent provisioning policy makes IDFC better placed compared to its peers in infra financing. The growth in IDFC’s outstanding disbursements remained well-diversified across telecom, energy and transportation segments. Analysts expect IDFC to report an EPS of Rs 11 and Rs 13 and estimated adjusted book value (for investment in other ventures) of Rs 82 and Rs 92 for 2012-13 and 2013-14, respectively. Maintain Buy.

Motilal Oswal Securities

BIOCON
Reco price/date: Rs 217/May 21;
Current/Target price: Rs 215/Rs 186
Biocon's (BIOS) shares have had an uninspiring run after the termination of the Pfizer deal, which dealt a big blow to its biosimilar insulin aspirations. While the deal is now terminated, it would continue to throw its shadow over future earnings, thanks to an aggressive accounting policy that would see BIOS shift biosimilar insulin R&D costs off the P&L. This, along with use of a creative transaction structure for AxiCorp, leaves analyst frustrated with corporate governance standards in the company, and they have downgraded their accounting and corporate governance rating from amber to red. Stripping out biosimilar insulin (90 per cent valuation haircut) and Dificid, BIOS is currently trading at 12 times FY13 estimated earnings. Espirito has cut its fair value by 47 per cent to Rs 186 (from Rs 350 earlier). Downgrade to sell.

Espirito Santo Securities


Note: Reco price/date refers to the price and date at which the recommendation was made. Target price refers to the fair value of the stock as per the said brokerage

image
Business Standard
177 22

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

More News

  • Rating agency shares soar on corporate bond Rating agency shares soar on corporate bond boost
  • Moody’s RBI norms on corporate bonds credit positive, says Moody's

STOCK WATCH

Company Price() Chg(%)
Trident 56.00 12.45
VST Inds. 2296.20 10.12
GRUH Finance 345.20 9.33
J B Chem & Pharm 336.60 7.90
Century Textiles 709.85 5.92
> More on BSE Gainers
Company Price() Chg(%)
Trident 56.45 13.13
Future Lifestyle 137.65 10.92
GRUH Finance 346.05 9.46
VST Inds. 2284.90 9.22
J B Chem & Pharm 336.50 7.71
> More on NSE Gainers
Company Price() Chg(%)
Welspun India 49.70 -8.64
Shilpa Medicare 553.00 -7.82
Piramal Enterp. 1851.10 -5.41
Jaypee Infratec. 9.21 -4.76
Avanti Feeds 534.10 -4.20
> More on BSE Gainers
Company Price() Chg(%)
Welspun India 49.40 -8.60
Shilpa Medicare 551.70 -7.87
IDBI Bank 70.45 -6.38
Jaypee Infratec. 9.10 -5.70
Piramal Enterp. 1847.10 -5.48
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard